PlainPharmaWatch

CMS Open Payments · Tool

Biofrontera Bioscience GmbH vs Trillium Therapeutics USA, LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Payment Overview

Total Payments
$1.3M
% of Industry
0.0%
Transactions
150
Avg per Transaction
$9.0K
Recipients
0
Avg per Recipient
$0.00
Payment Types
0
Top Payment Type
-
Total Payments
$1.3M
% of Industry
0.0%
Transactions
403
Avg per Transaction
$3.3K
Recipients
0
Avg per Recipient
$0.00
Payment Types
0
Top Payment Type
-

Highlighted values indicate the higher figure for each metric.

Total payments compared

Biofrontera Bioscience GmbH vs Trillium Therapeutics USA, LLC - total reported payments in CMS Open Payments PY2024

Trillium Therapeutics USA,…$1.3MBiofrontera Bioscience GmbH$1.3M

Summary Comparison

Metric Biofrontera Bioscience GmbH Trillium Therapeutics USA, LLC
Total Payments $1.3M $1.3M
% of Industry Total 0.0% 0.0%
Transaction Count 150 403
Avg per Transaction $9.0K $3.3K
Recipient Count 0 0
Avg per Recipient $0.00 $0.00
Payment Type Count 0 0
Top Payment Type - -

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.